Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX55 in advanced solid tumors
NCT04169178Phase 1Unknown
- Sponsor
- Henlix Biotech
- Start
- Mar 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HLX55 in solid tumor, gastric cancer (GC), non-small cell lung cancer (NSCLC) and 1 more (5 arms), sponsored by Henlix Biotech. Primary endpoints: Safety and tolerability up to 2 years, Maximum Tolerated Dose up to 2 years and 2 more. Status: unknown.
02
Drugs
HLX55
03
Conditions
solid tumorgastric cancer (GC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04169178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169178.